182 related articles for article (PubMed ID: 36864257)
21. Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.
Suzuki Y; Sakakibara A; Shimada K; Shimada S; Ishikawa E; Nakamura S; Kato S; Takahara T; Asano N; Satou A; Kohno K
Pathol Int; 2019 Jan; 69(1):13-20. PubMed ID: 30601579
[TBL] [Abstract][Full Text] [Related]
22. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
[TBL] [Abstract][Full Text] [Related]
23. Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome.
Augé H; Notarantonio AB; Morizot R; Quinquenel A; Fornecker LM; Hergalant S; Feugier P; Broséus J
Front Immunol; 2020; 11():594841. PubMed ID: 33381116
[TBL] [Abstract][Full Text] [Related]
24. Correlation study of PD-L1, CD4, CD8, and PD-1 in primary diffuse large B-cell lymphoma of the central nervous system.
Liu B; Yan S; Li S; Zhang Q; Yang M; Yang L; Ma J; Li X
Pathol Res Pract; 2022 Nov; 239():154008. PubMed ID: 36183436
[TBL] [Abstract][Full Text] [Related]
25. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
26. The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified.
Slak TC; Miceska S; Gasljevic G; Boltezar L; Kloboves-Prevodnik V
Radiol Oncol; 2024 Mar; 58(1):99-109. PubMed ID: 38378036
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.
Hongo T; Yamamoto H; Jiromaru R; Yasumatsu R; Kuga R; Nozaki Y; Hashimoto K; Matsuo M; Wakasaki T; Tamae A; Taguchi K; Toh S; Masuda M; Nakagawa T; Oda Y
Mod Pathol; 2021 Nov; 34(11):1966-1978. PubMed ID: 34218257
[TBL] [Abstract][Full Text] [Related]
29. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
30. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint.
Zhao L; Liu Y; Zhang J; Liu Y; Qi Q
Cell Death Dis; 2019 Sep; 10(10):731. PubMed ID: 31570691
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
[TBL] [Abstract][Full Text] [Related]
32. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
[TBL] [Abstract][Full Text] [Related]
33. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
34. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
Song MK; Park BB; Uhm J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
[TBL] [Abstract][Full Text] [Related]
35. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
[TBL] [Abstract][Full Text] [Related]
36. Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3.
Wu S; Shi X; Wang J; Wang X; Liu Y; Luo Y; Mao F; Zeng X
Front Immunol; 2021; 12():561793. PubMed ID: 33717059
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression.
Jiang XN; Yu BH; Yan WH; Lee J; Zhou XY; Li XQ
Oncoimmunology; 2020; 9(1):1683346. PubMed ID: 32002294
[No Abstract] [Full Text] [Related]
38. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.
Li L; Sun R; Miao Y; Tran T; Adams L; Roscoe N; Xu B; Manyam GC; Tan X; Zhang H; Xiao M; Tzankov A; Visco C; Dybkaer K; Bhagat G; Tam W; Hsi ED; van Krieken JH; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Zhang M; Winter JN; Medeiros LJ; Rassidakis GZ; Vaupel CA; Li Y; Dakappagari N; Xu-Monette ZY; Young KH
Mod Pathol; 2019 Jun; 32(6):741-754. PubMed ID: 30666052
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings.
Karakatsanis S; S Papadatos S; Syrigos N; Marinos L; Pouliou E; Papanikolaou A
J BUON; 2021; 26(2):569-579. PubMed ID: 34077007
[TBL] [Abstract][Full Text] [Related]
40. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.
Wang Y; Sinha S; Wellik LE; Secreto CR; Rech KL; Call TG; Parikh SA; Kenderian SS; Muchtar E; Hayman SR; Koehler AB; Van Dyke DL; Leis JF; Slager SL; Dong H; Kay NE; He R; Ding W
Blood Cancer J; 2021 May; 11(5):86. PubMed ID: 33972504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
